Two Sigma Advisers
RVNC

Two Sigma Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

Two Sigma Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,300
Closed -$26.5K – 2573
2024
Q2 		$26.5K Buy
+10,300
New +$35.2K ﹤0.01% 2391
2023
Q3 		– Sell
-1,124,000
Closed -$28.4M – 2615
2023
Q2 		$28.4M Sell
1,124,000
-425,500
-27% -$13.3M 0.07% 246
2023
Q1 		$49.9M Buy
1,549,500
+383,800
+33% +$12M 0.13% 165
2022
Q4 		$21.5M Buy
1,165,700
+658,200
+130% +$15.1M 0.06% 315
2022
Q3 		$13.7M Buy
507,500
+399,100
+368% +$8.1M 0.04% 414
2022
Q2 		$1.5M Buy
+108,400
New +$1.67M ﹤0.01% 1375
2020
Q4 		– Sell
-64,600
Closed -$1.62M – 2640
2020
Q3 		$1.62M Buy
64,600
+3,400
+6% +$89.1K ﹤0.01% 1272
2020
Q2 		$1.5M Buy
61,200
+11,600
+23% +$229K ﹤0.01% 1368
2020
Q1 		$734K Buy
+49,600
New +$1.03M ﹤0.01% 1633
2019
Q3 		– Sell
-16,600
Closed -$215K – 2427
2019
Q2 		$215K Sell
16,600
-19,600
-54% -$247K ﹤0.01% 2112
2019
Q1 		$571K Buy
+36,200
New +$628K ﹤0.01% 1741
2018
Q4 		– Sell
-19,000
Closed -$472K – 2490
2018
Q3 		$472K Sell
19,000
-22,306
-54% -$607K ﹤0.01% 1816
2018
Q2 		$1.13M Buy
41,306
+19,006
+85% +$571K ﹤0.01% 1563
2018
Q1 		$687K Buy
22,300
+12,700
+132% +$409K ﹤0.01% 1699
2017
Q4 		$343K Buy
+9,600
New +$276K ﹤0.01% 1899
2015
Q3 		– Sell
-9,800
Closed -$313K – 2017
2015
Q2 		$313K Sell
9,800
-16,700
-63% -$429K ﹤0.01% 1599
2015
Q1 		$549K Buy
+26,500
New +$458K ﹤0.01% 1303

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Two Sigma Advisers's RVNC Position: Q3 2024 in Review

Two Sigma Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 10,300 shares — an estimated $26.5K sold.

Two Sigma Advisers first reported a position in RVNC in Q1 2015 and held it in 17 quarters. The position peaked at $49.9M in Q1 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Two Sigma Advisers reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 10,300 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $26.5K.
  • Two Sigma Advisers first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 17 quarters.
  • Two Sigma Advisers's Revance Therapeutics, Inc. position peaked at $49.9M in Q1 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Two Sigma Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.